Compare iShares MSCI South Korea ETF (EWY) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Humana Inc — how do they compare? iShares MSCI South Korea ETF trades at $162.86, while Humana Inc trades at $392.92 (market cap $48.96B). The key difference: Humana Inc pays a 0.87% dividend while iShares MSCI South Korea ETF pays none, and Humana Inc is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals.
| EWY | HUM | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $409.42 |
52-Week Low | $70.65 | $163.67 |
Market Cap | — | $48.96B |
Enterprise Value | — | $58.00B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY is trading at $163.67, down 7.52% with significant volatility driven by its heavy concentration in South Korean semiconductor giants Samsung and SK Hynix. The ETF has entered bear market territory, reflecting global tech sector pressures and foreign investor selling. Technical indicators show bearish momentum with RSI near oversold levels at 28, while support sits at $157. Recent news highlights the Kospi Index's 21% decline from YTD highs, creating both risk and potential opportunity.
The outlook remains challenged by semiconductor cycle volatility and concentrated exposure, but long-term AI demand fundamentals provide potential upside. Key risks include single-stock concentration, foreign capital flows, and global tech sentiment shifts. Investors should weigh near-term volatility against structural semiconductor growth drivers.
Humana (HUM) trades at $395.78, down 2.68% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $10.31, beating expectations, and maintains a P/E of 43.52 and P/S of 0.36. Recent news highlights margin recovery targets and expansion through CenterWell, while investigations into insider sales and cost statements introduce uncertainty.
Outlook is mixed: analyst consensus is $354.33 with 61% hold ratings, reflecting caution despite growth initiatives. Key risks include Medicare Advantage margin pressures and legal scrutiny, but revenue growth to $137.2B in 2026 and a dividend payment in July offer support. Investors should weigh profitability trends against valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
